Enzon Pharmaceuticals, Inc. Stock

Equities

ENZN

US2939041081

Biotechnology & Medical Research

Market Closed - OTC Markets 01:33:31 2024-04-26 pm EDT 5-day change 1st Jan Change
0.0834 USD -5.17% Intraday chart for Enzon Pharmaceuticals, Inc. +15.33% -10.79%
Sales 2022 26K Sales 2023 - Capitalization 6.94M
Net income 2022 - Net income 2023 1M EV / Sales 2022 -1,103 x
Net cash position 2022 46.98M Net cash position 2023 47.01M EV / Sales 2023 -
P/E ratio 2022
-12.5 x
P/E ratio 2023
70.9 x
Employees 1
Yield 2022 *
-
Yield 2023
-
Free-Float 89.16%
More Fundamentals * Assessed data
Dynamic Chart
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Enzon Pharmaceuticals, Inc. Announces Executive Changes CI
Enzon Pharmaceuticals, Inc. Appoints Richard L. Feinstein as Secretary CI
More news
1 day-5.17%
1 week+15.33%
Current month-11.64%
1 month-1.18%
3 months-1.88%
6 months-44.26%
Current year-10.79%
More quotes
1 week
0.07
Extreme 0.072
0.09
1 month
0.06
Extreme 0.06
0.10
Current year
0.06
Extreme 0.06
0.12
1 year
0.06
Extreme 0.06
0.22
3 years
0.06
Extreme 0.06
0.76
5 years
0.02
Extreme 0.02
0.85
10 years
0.02
Extreme 0.02
1.88
More quotes
Managers TitleAgeSince
Chief Executive Officer 80 13-12-12
Members of the board TitleAgeSince
Chairman 71 20-08-03
Director/Board Member 67 22-06-30
Director/Board Member 68 20-08-03
More insiders
Date Price Change Volume
24-04-26 0.0834 -5.17% 900
24-04-25 0.088 +12.87% 3,991
24-04-23 0.078 +7.75% 125

Delayed Quote OTC Markets, April 26, 2024 at 01:33 pm EDT

More quotes
Enzon Pharmaceuticals, Inc. (Enzon) is an acquisition vehicle company. The Company intends to become an acquisition platform. The Company utilizes its net operating loss carryforwards (NOLs) and improves stockholder value. It manages its source of royalty revenues from existing licensing arrangements with other companies.
More about the company